Exploring New Treatment Options for Cancer Patients

Syndax is developing entinostat and SNDX-6352 in multiple cancer indications. See below for further details.

  • Entinostat

    Entinostat as Immunotherapy

    ENCORE 601 / KEYNOTE 142NCT02437136
    Collaboration with Merck

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer.

    ENCORE 602NCT02708680
    Collaboration with Genentech

    A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with Metastatic Triple Negative Breast Cancer, with a Phase 1b Lead in Phase.

    ENCORE 603NCT02915523
    Collaboration with Merck KGaA and Pfizer

    A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in.

    Entinostat in HR+ Breast Cancer

    Sponsored by NCI/ECOG-ACRIN Cancer Research Group

    A Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor Positive Advanced Breast Cancer.

    Click here to visit the E2112 website >>

    See all our Collaborations

  • SNDX-6352


    A Phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors.


    A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD Activity of SNDX-6352 in Subjects With Active cGVHD Who Have Received at Least 2 Lines of Prior Therapy, Including Ibrutinib.